CZ2003225A3 - Derivát imidazolu a farmaceutický prostředek, který ho obsahuje - Google Patents
Derivát imidazolu a farmaceutický prostředek, který ho obsahuje Download PDFInfo
- Publication number
- CZ2003225A3 CZ2003225A3 CZ2003225A CZ2003225A CZ2003225A3 CZ 2003225 A3 CZ2003225 A3 CZ 2003225A3 CZ 2003225 A CZ2003225 A CZ 2003225A CZ 2003225 A CZ2003225 A CZ 2003225A CZ 2003225 A3 CZ2003225 A3 CZ 2003225A3
- Authority
- CZ
- Czechia
- Prior art keywords
- carbon atoms
- formula
- imidazol
- cyclobutyl
- cis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22172400P | 2000-07-31 | 2000-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ2003225A3 true CZ2003225A3 (cs) | 2004-02-18 |
Family
ID=22829075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ2003225A CZ2003225A3 (cs) | 2000-07-31 | 2001-07-25 | Derivát imidazolu a farmaceutický prostředek, který ho obsahuje |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1305295A1 (ru) |
| JP (2) | JP4166084B2 (ru) |
| KR (1) | KR20030019644A (ru) |
| CN (1) | CN1444567A (ru) |
| AP (1) | AP2001002232A0 (ru) |
| AR (1) | AR032629A1 (ru) |
| AU (1) | AU2001270944A1 (ru) |
| BG (1) | BG107469A (ru) |
| BR (1) | BR0112862A (ru) |
| CA (1) | CA2418115A1 (ru) |
| CR (1) | CR6861A (ru) |
| CZ (1) | CZ2003225A3 (ru) |
| DO (1) | DOP2001000220A (ru) |
| EA (1) | EA200300097A1 (ru) |
| EC (1) | ECSP034445A (ru) |
| EE (1) | EE200300049A (ru) |
| GT (1) | GT200100147A (ru) |
| HR (1) | HRP20030048A2 (ru) |
| HU (1) | HUP0303069A3 (ru) |
| IL (1) | IL153787A0 (ru) |
| IS (1) | IS6662A (ru) |
| MA (1) | MA26932A1 (ru) |
| MX (1) | MXPA03000939A (ru) |
| NO (1) | NO20030472L (ru) |
| NZ (1) | NZ523272A (ru) |
| OA (1) | OA12345A (ru) |
| PA (1) | PA8523701A1 (ru) |
| PE (1) | PE20020337A1 (ru) |
| PL (1) | PL365134A1 (ru) |
| SK (1) | SK1042003A3 (ru) |
| SV (1) | SV2002000571A (ru) |
| TN (1) | TNSN01114A1 (ru) |
| UY (1) | UY26862A1 (ru) |
| WO (1) | WO2002010141A1 (ru) |
| ZA (1) | ZA200300819B (ru) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| AU2003251721A1 (en) | 2002-06-14 | 2003-12-31 | Laboratoires Serono Sa | Azole methylidene cyanide derivatives and their use as protein kinase modulators |
| US7141561B2 (en) | 2002-07-25 | 2006-11-28 | Sanofi-Aventis Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
| DE10233817A1 (de) * | 2002-07-25 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
| WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| DK1730119T3 (da) * | 2004-03-23 | 2008-08-11 | Pfizer Prod Inc | Imidazolforbindelser til behandling af neurodegenerative forstyrrelser |
| EP1751139B1 (en) | 2004-04-30 | 2011-07-27 | Bayer HealthCare LLC | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| MX2007003111A (es) | 2004-09-21 | 2007-05-24 | Astellas Pharma Inc | Derivados de aminoalcohol. |
| EP1885454A2 (en) | 2005-05-04 | 2008-02-13 | DeveloGen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| CA2619068A1 (en) | 2005-09-22 | 2007-03-29 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| EA200801716A1 (ru) | 2006-01-18 | 2009-04-28 | Амген Инк. | Тиазольные соединения и их применение |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| CN101573352A (zh) | 2006-10-21 | 2009-11-04 | 艾博特股份有限两合公司 | 杂环化合物和其作为糖原合酶激酶3抑制剂的用途 |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| ES2418457T3 (es) * | 2008-04-24 | 2013-08-13 | Abbott Gmbh & Co. Kg | Derivados de 1-(7-(hexahidropirrolo[3,4-c]pirrol-2(1H)-il)quinolin-4-il)-3-(pirazin-2-il)urea y compuestos relacionados como inhibidores de glucógeno sintasa cinasa 3 (GSK-3) |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN103119035B (zh) | 2010-09-27 | 2015-09-30 | 雅培股份有限两合公司 | 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途 |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| JP6329170B2 (ja) | 2012-12-07 | 2018-05-23 | ケモセントリックス，インコーポレイティド | ジアゾールラクタム |
| WO2014100735A2 (en) * | 2012-12-21 | 2014-06-26 | Chemocentryx, Inc. | Diazole amides |
| WO2015119249A1 (ja) * | 2014-02-07 | 2015-08-13 | 国立大学法人東京医科歯科大学 | 筋形成促進剤、筋萎縮抑制剤、医薬組成物及びｔａｚ活性化剤 |
| PL3344273T3 (pl) | 2015-08-31 | 2020-06-01 | Nutramax Laboratories, Inc. | Kompozycje zawierające magnolię, korkowiec, teaninę i/lub białko serwatkowe |
| GB201605126D0 (en) * | 2016-03-24 | 2016-05-11 | Univ Nottingham | Inhibitors and their uses |
| US10568870B2 (en) | 2016-04-07 | 2020-02-25 | Chemocentryx, Inc. | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors |
| CN110963996B (zh) * | 2017-10-25 | 2022-09-09 | 西南大学 | 含苯乙酮取代基的靛红唑醇类化合物及其制备方法和医药应用 |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| GB201908424D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
| US10590087B1 (en) | 2019-08-09 | 2020-03-17 | Pfizer Inc. | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
| US11884634B2 (en) | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
| CN112250636A (zh) * | 2020-11-09 | 2021-01-22 | 广西科技大学 | 5-氨基咪唑类化合物及其合成方法 |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| ZA987383B (en) * | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| ZA987385B (en) * | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| JP4533534B2 (ja) * | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | グリコーゲンシンターゼキナーゼ３のインヒビター |
| WO2000021550A2 (en) * | 1998-10-13 | 2000-04-20 | President And Fellows Of Harvard College | Methods and compositions for treating neurodegenerative diseases |
| CO5160260A1 (es) * | 1999-02-19 | 2002-05-30 | Lilly Co Eli | Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido |
| DE69912808T2 (de) * | 1999-12-08 | 2004-09-30 | Centre National De La Recherche Scientifique (C.N.R.S.) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel |
-
2001
- 2001-07-23 GT GT200100147A patent/GT200100147A/es unknown
- 2001-07-25 AU AU2001270944A patent/AU2001270944A1/en not_active Abandoned
- 2001-07-25 EP EP01949833A patent/EP1305295A1/en not_active Withdrawn
- 2001-07-25 IL IL15378701A patent/IL153787A0/xx unknown
- 2001-07-25 PL PL01365134A patent/PL365134A1/xx not_active Application Discontinuation
- 2001-07-25 EA EA200300097A patent/EA200300097A1/ru unknown
- 2001-07-25 OA OA1200300017A patent/OA12345A/en unknown
- 2001-07-25 NZ NZ523272A patent/NZ523272A/en unknown
- 2001-07-25 EE EEP200300049A patent/EE200300049A/xx unknown
- 2001-07-25 CA CA002418115A patent/CA2418115A1/en not_active Abandoned
- 2001-07-25 KR KR10-2003-7001455A patent/KR20030019644A/ko not_active Application Discontinuation
- 2001-07-25 CZ CZ2003225A patent/CZ2003225A3/cs unknown
- 2001-07-25 PE PE2001000752A patent/PE20020337A1/es not_active Application Discontinuation
- 2001-07-25 MX MXPA03000939A patent/MXPA03000939A/es active IP Right Grant
- 2001-07-25 CN CN01813397A patent/CN1444567A/zh active Pending
- 2001-07-25 BR BR0112862-0A patent/BR0112862A/pt not_active IP Right Cessation
- 2001-07-25 SK SK104-2003A patent/SK1042003A3/sk not_active Application Discontinuation
- 2001-07-25 WO PCT/IB2001/001335 patent/WO2002010141A1/en not_active Application Discontinuation
- 2001-07-25 HU HU0303069A patent/HUP0303069A3/hu unknown
- 2001-07-25 JP JP2002516273A patent/JP4166084B2/ja not_active Expired - Fee Related
- 2001-07-26 AP APAP/P/2001/002232A patent/AP2001002232A0/en unknown
- 2001-07-27 DO DO2001000220A patent/DOP2001000220A/es unknown
- 2001-07-27 SV SV2001000571A patent/SV2002000571A/es not_active Application Discontinuation
- 2001-07-30 TN TNTNSN01114A patent/TNSN01114A1/fr unknown
- 2001-07-30 AR ARP010103637A patent/AR032629A1/es unknown
- 2001-07-30 UY UY26862A patent/UY26862A1/es not_active Application Discontinuation
- 2001-07-31 PA PA20018523701A patent/PA8523701A1/es unknown
-
2002
- 2002-12-18 CR CR6861A patent/CR6861A/es not_active Application Discontinuation
- 2002-12-19 IS IS6662A patent/IS6662A/is unknown
-
2003
- 2003-01-16 BG BG107469A patent/BG107469A/bg unknown
- 2003-01-20 MA MA27004A patent/MA26932A1/fr unknown
- 2003-01-22 EC EC2003004445A patent/ECSP034445A/es unknown
- 2003-01-24 HR HR20030048A patent/HRP20030048A2/hr not_active Application Discontinuation
- 2003-01-29 ZA ZA200300819A patent/ZA200300819B/en unknown
- 2003-01-30 NO NO20030472A patent/NO20030472L/no not_active Application Discontinuation
-
2008
- 2008-05-19 JP JP2008131176A patent/JP2008255123A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ2003225A3 (cs) | Derivát imidazolu a farmaceutický prostředek, který ho obsahuje | |
| US20060149066A1 (en) | Imidazole derivatives | |
| CZ2003468A3 (cs) | Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy | |
| DE60208630T2 (de) | Thiazolderivate und ihre Verwendung als cdk-Inhibitoren | |
| US8362065B2 (en) | Carbazole carboxamide compounds useful as kinase inhibitors | |
| US20050209297A1 (en) | Pyrazole derivatives | |
| WO2009004427A2 (en) | Benzimidazole derivatives | |
| NZ525892A (en) | Phenylacetamido- pyrazole derivatives their use as antitumor agents and preparation process thereof | |
| CA2753560A1 (en) | Inhibitors of phosphatidylinositol 3-kinase | |
| WO2012044090A2 (ko) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 | |
| KR102466810B1 (ko) | 포유류 티로신 키나제 ror1 활성의 저해제로서 유용한 2-페닐이미다조[4,5-b]피리딘-7-아민 유도체 | |
| AU2010258903A1 (en) | Inhibitors of phosphatidylinositol 3-kinase | |
| US20020103185A1 (en) | Pyrazole derivatives | |
| US20030083352A1 (en) | Synthesis of imidazole intermediates |